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ABSTRACT: Natural products and their analogues are often
challenging to synthesize due to their complex scaffolds and
embedded functional groups. Solely relying on engineering the
biosynthesis of natural products may lead to limited compound
diversity. Integrating synthetic biology with synthetic chemistry
allows rapid access to much more diverse portfolios of xenobiotic
compounds, which may accelerate the discovery of new
therapeutics. As a proof-of-concept, by supplementing an
Escherichia coli strain expressing the violacein biosynthesis pathway
with 5-bromo-tryptophan in vitro or tryptophan 7-halogenase
RebH in vivo, six halogenated analogues of violacein or
deoxyviolacein were generated, demonstrating the promiscuity of
the violacein biosynthesis pathway. Furthermore, 20 new derivatives were generated from 5-brominated violacein analogues via the
Suzuki−Miyaura cross-coupling reaction directly using the crude extract without prior purification. Herein we demonstrate a flexible
and rapid approach to access a diverse chemical space that can be applied to a wide range of natural product scaffolds.
■ INTRODUCTION
The total synthesis of natural products and their analogues has
often been challenging and costly due to their structural
complexities;1 however, greater chemical space may be accessed
through the utilization of synthetic chemistry methodologies
and reagents compared with employing enzyme-catalyzed
biosynthesis alone. Combining biosynthesis with chemical
synthesis represents a powerful approach for rapidly generating
new analogues of complex natural products and libraries of
chemical derivatives suitable for screening and structure−
activity relationship (SAR) assays,2,3 leading to the discovery of
new and more potent compounds. The generation of such
analogues can enable improvement in the bioactivity and
bioavailability, as illustrated, for example, by analogues of the
“last-resort” antibiotic vancomycin, with a >200-fold improve-
ment of potency compared with vancomycin in resistant
Enterococci strains.4 In another study, the addition of a sterically
unhindered primary amine group to a Gram-positive antibiotic
deoxynybomycin expanded its antimicrobial activity to multi-
drug-resistant Gram-negative pathogenic strains.5
As a proof-of-concept, we have focused on the violacein
biosynthetic pathway. Violacein (1), a violet pigment first
isolated from the bacterium Chromobacterium violaceum, is part
of the bisindole biosynthetic family that utilizes L-tryptophan as
the starting substrate. The violacein pathway is encoded within a
conserved operon of five genes (vioABCDE), whose gene
products catalyze a 14-electron oxidative biosynthesis pathway.6
The bisindole biosynthetic pathways have attracted considerable
interest because of their therapeutic potential for medical
applications, including antimicrobial, antiviral, trypanocidal, and
antitumorigenic properties.7 The violacein biosynthetic pathway
also produces deoxyviolacein (2) as a byproduct, and the
colored properties of violacein and deoxyviolacein make them
interesting targets for natural product pathway engineering, such
as promoter library screening,8 CRISPR-based multiplex
transcriptional regulation,9 or diverting pathway flux via
ribosomal-binding site (RBS) engineering.10
A study on oxyviolacein, a hydroxylated analogue of violacein
generated by feeding exogenous 5-hydroxy-L-tryptophan,11
showed bioactivity against a collection of pathogenic bacteria
and fungi strains,12 suggesting that violacein analogues may be a
good starting point for developing more potent antibiotics. A
similar rationally designed precursor-directed biosynthetic
strategy has also showed considerable success in generating
analogues of flavonoids.13 Other examples of using altered
biosynthetic pathways for analogue generation include the use of
various enzyme homologues from bisindole pathways,14,15
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interconversion of the biosynthetically related novobiocin and
clorobiocin aminocoumarin antibiotics,16 introduction of the
halogenase from the hormaomycin pathway to generate
clorobiocin analogues,17 and generation of chlorinated mono-
terpene indole alkaloids.18 A prominent strategy in generating
natural product analogues is GenoChemetics, where reactive
halogen handles are installed via engineered biosynthetic
pathways on natural products, which are subsequently
derivatized via living-culture-optimized cross-coupling reac-
tions, resulting in analogues of the antibiotic pacidamycin.19
Although the total chemical synthesis of violacein20,21 and some
substituted analogues22,23 has been reported, these syntheses are
challenging and low-yielding. Pathway manipulation could
represent a more flexible, sustainable, and rapid approach for
generating violacein analogues. In this study, we have applied
such approaches to generate 26 new violacein or deoxyviolacein
analogues via a combination of pathway engineering enabling
the enzymatic halogenation of the starting substrate tryptophan,
feeding brominated tryptophan, and further derivatization using
Suzuki−Miyaura cross-coupling directly in crude extracts
(Figure 1).
■ RESULTS AND DISCUSSION
VioA, the first enzyme in the violacein biosynthesis pathway,
oxidizes the substrate L-tryptophan to form the first pathway
intermediate indole-3-pyruvic acid imine (IPA imine). To
determine whether VioA would accept different tryptophan
analogues as substrates, we purified VioA (Figure S1) and
carried out VioA enzyme kinetic assays against various substrate
analogues including L-tryptophan (TRP), 4-fluoro-D,L-trypto-
phan (4FT), 5-methyl-D,L-tryptophan (5MeT), 6-fluoro-D,L-
tryptophan (6FT), and 7-methyl-D,L-tryptophan (7MeT).
These substrates were chosen to probe the effect of substituted
positions of tryptophan indole rings on VioA-substrate kinetics.
4FT, 6FT, and 7MeT were shown to exhibit a wide range of
analogue conversion yields in our previous study on substrate-
fed violacein analogues,24 whereas VioA was shown to have a
higher activity against 5MeT than TRP.25 The kinetics of VioA
against L-tryptophan (kcat = 3.04 s
−1, 95% CI [2.17 to 5.33]; KM
= 447 μM, 95% CI [255 to 977], kcat/KM = 6.80 s
−1 mM−1) have
been previously determined with both UV-monitored substrate
depletion and coupled peroxidase assays, although only the
kinetic data generated from the substrate depletion assay were
reported (kcat = 3.38 ± 0.32 s
−1, KM = 31 ± 11 μM).
6 The
discrepancy between the reported values and our data could be
due to the difference in the assay conditions, the kinetic models
chosen, or the multiple reaction steps involved in the coupled
peroxidase assay. Among the substituted tryptophan substrates,
6FT exhibited the highest kcat/KM value (13.9 s
−1 mM−1),
followed by 7MeT (11.2 s−1 mM−1), 5MeT (3.18 s−1 mM−1),
and 4FT (<0.0658 s−1 mM−1) (Figure 2a,b, Table S1). We
cannot accurately estimate the kcat/KM value of VioA against
4FT because the best-fit value of KM, 8.307 mM is beyond the
range of substrate concentration tested (up to 5 mM).
Nonetheless, this shows that VioA exhibits a much higher
activity against 6FT compared with other substituted
tryptophan analogues tested, indicating a strong preference at
the six-substituted position. Interestingly, our data show that
VioA has only 47% relative activity against 5MeT compared with
L-tryptophan, in contrast with previous characterization,25 but
this is perhaps due to the difference in kinetic models chosen for
our data (substrate inhibition) as opposed to the Michaelis−
Menten model in the previous study.
To determine if the substrate kinetics differences were due to
alterations in the substrate binding, we next solved the crystal
structures of apo VioA (PDB 6ESD) and VioA complexed with
TRP (PDB 6G2P), 4FT (PDB 6FW7), 5MeT (PDB 6FW8),
6FT (PDB 6FW9), and 7MeT (PDB 6FWA) with resolutions
ranging from 2.4 to 3.0 Å (Figure 2c,d, data statistics in Table
S2). Our apo VioA structure is nearly identical to the published
Figure 1. Schematics of the GenoChemetic approach used in this study. Analogues of violacein (1) or deoxyviolacein (2) can be generated via the in
vivo halogenation of tryptophan by expressing flavin reductase RebF and tryptophan halogenase RebH with the rest of the violacein pathway. Further
derivatization via Suzuki−Miyaura cross-coupling lead to new synthetic analogues. Available enzyme structures are shown and correspond to VioA
(PDB 6G2P), VioD (PDB 3C4A), VioE (PDB 3BMZ), and RebH (PDB 2E4G) as well as models generated in silico by Phyre2 (http://www.sbg.bio.
ic.ac.uk/phyre2) for RebO, RebD, VioB, VioC, and RebF.
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apo VioA structure (PDB 5G3T, rmsd = 0.940 Å), whereas our
tryptophan-bound structure (PDB 6G2P) is also very similar to
both the inhibitor-bound VioA25 (PDB 5G3U, 0.586 Å) and the
tryptophan-bound C395A VioA mutant26 (PDB 5ZBD, 0.689
Å). The four-substituted tryptophan-substrate-bound VioA
structures are also virtually identical to the tryptophan-bound
VioA structure, with an rmsd in the range of 0.304 to 0.419 Å.
The active site of VioA reveals several key residues surrounding
the C4 to C7 positions of the tryptophan substrate indole ring.
Of the four positions, C4 andC7 have themost space around the
binding site pocket compared with C5 and C6 due to Asp311
and Ala145 side chains (Figure 2c), suggesting that VioA would
have the lowest affinity for tryptophan analogues with
substituent groups at the C5 and C6 positions. However, the
interatomic distances between the respective Cα atom or amine
nitrogen atom and the N5 of the FAD cofactor are conserved for
all of the analogues (between 3.93 and 4.69 Å for the Cα atom
and 3.62 and 5.63 Å for amine nitrogen) and are similar to that of
the TRP-bound structure (3.93 Å for Cα atom and 5.07 Å for
amine nitrogen) (Figure S2). This showed that all of the
analogues can bind VioA in a catalytically active but slightly
different conformation. Interestingly, the hydrogen bonding
between Arg64 and Tyr309 and the carboxylate group of all
substrate analogues is conserved, as are the positions of the other
active-site residues (Figure 2d). Our data clearly show that the
VioA active site can flexibly accommodate a variety of
tryptophan substrate analogues for catalysis.
Recently, we have generated a wide range of violacein and
deoxyviolacein analogues from E. coli cells that were expressing a
synthetic violacein biosynthesis pathway vioABCDE with added
substituted tryptophans, and these crude extracts were tested
against the malarial parasite Plasmodium falciparum.24 Because
of the promiscuity of the enzymes involved in the biosynthesis of
violacein, we rationalized that a combination of enzymes from
closely related bisindole biosynthesis pathways could generate
compatible tryptophan analogues, leading to other interesting
new-to-nature analogues of violacein that might otherwise be
difficult to synthesize. Rebeccamycin is a closely related
bisindole where the biosynthetic pathway contains several
genes, including rebO (Q8KHS0) and rebD (Q8KHV6), which
are homologous to vioA (Q9S3V1) and vioB (Q9S3V0),
respectively. In addition, the pathway also consists of a
tryptophan 7-halogenase RebH and its associated flavin
reductase RebF that are responsible for generating 7-chloro-L-
Figure 2. VioA substrate kinetics and structure. (a) Michaelis−Menten model is fitted on the VioA kinetics data against 4-fluoro-D,L-tryptophan
(4FT). (b) Substrate inhibition model fitted on VioA kinetics data against L-tryptophan (TRP), 5-methyl-D,L-tryptophan (5MeT), 6-fluoro-D,L-
tryptophan (6FT), and 7-methyl-D,L-tryptophan (7MeT). Data represent the mean and error bars represent the SD of three independent experiments
carried out on three separate days. Kinetic parameters are in Table S1. (c) Binding site pocket showing the space enclosed by the residues (magenta)
around L-tryptophan (gray with elemental color). The carbon positions of the tryptophan indole ring are labeled. (d) Superimposition of the active
sites of VioA structures complexed with L-tryptophan (TRP, magenta), 4-fluoro-L-tryptophan (4FT, yellow), 5-methyl-L-tryptophan (5MeT, light
gray), 6-fluoro-L-tryptophan (6FT, dark blue), and 7-methyl-L-tryptophan (7MeT, brown) in stick representation. Side chains surrounding the
tryptophan ligand are labeled. Note that 6FT has two conformers fitted in the density map. (See Figure S2.)
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Figure 3. Generation of 7-chloro analogues of violacein and deoxyviolacein via in vivo halogenation. (a) Schematic of the hybrid rebeccamycin−
violacein pathway enzymes that lead to 7-chloro analogues of violacein (3) and deoxyviolacein (4a−c), as analyzed by LC-HRMS/MS (Table S3). (b)
Four constructs constituting various combinations of violacein and rebeccamycin biosynthetic genes to generate chlorinated violacein analogues.
Pathway symbols were drawn using the SBOL visual standard for biological parts. (c) Representative extracted ion chromatograms (EICs) targeting
[M + H]+m/z of 1, 3, and 4a−c detected from ethanol extracts of E. coli cells harboring one of the pathway combinations in panel b. The compounds
detected are shown with a dotted line to indicate the approximate retention times. Compound 2 is not shown here because it elutes at the same
retention time as 3. The VioABCDE sample was run on a separate day, so the retention time of 1 is slightly later than that of the other three samples. (d)
Area under curves of m/z species extracted at the MS/MS level from the TIC of ethanol extracts from cells harboring the respective pathway
combination in panel b. Vio analogue refers to 3, whereas DV analogues refer to 4a−c. (e) Percentage compositions of Vio and DV analogues from
different E. coli strains expressing hybrid Reb/Vio pathway variants. Data show the mean and SD of biological duplicates. (f) Percentage compositions
of 7-chloro analogues of violacein and deoxyviolacein extracted from E. coli expressing RebFHOD+VioCDE with different combinations of medium
(J23108, green) and weak (J23114, gray) promoters controlling the expression of RebF, RebH, and VioD. Data show the mean and SD of biological
triplicates.
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tryptophan from L-tryptophan via a chloraminelysine inter-
mediate.27,28 As a proof-of-principle, we combined the
rebeccamycin (Reb) and violacein (Vio) biosynthetic operons
via Golden Gate cloning29,30 to generate C7-chlorinated
violacein analogues, which we were able to successfully produce
in E. coli cells (Figure 3a,b) identified via LC-HRMS/MS
(Figure 3c, Table S3). We found that although the RebOD
+VioCDE strain (lacking RebFH) did not produce any
chlorinated analogues of violacein, it was able to functionally
substitute VioAB to produce violacein and deoxyviolacein.6
Next, by comparing RebFH+VioABCDE and RebFHOD
+VioCDE (where RebOD replaced VioAB) strains, we observed
that RebOD increased the proportion of chlorinated analogues
from 6 to 33% when compared with VioAB (Figure 3d,e). This
was likely due to the fact that RebO has a kcat/Km value that is 57
times higher for 7-Cl-L-tryptophan than for L-tryptophan,31 and
thus RebO and RebD preferentially accept the 7-chloro
analogue of L-tryptophan and IPA imine, respectively, producing
the 7-chlorinated intermediate for downstream enzymes in the
violacein biosynthesis pathway. By replacing the weak promoter
J23114 for RebF and RebH with a medium strength promoter
J23108 (strains S2 and S3), we observed a total analogue
increase of nearly 30% (Figure 3f). We also observed an increase
in 7′-chloro-violacein (3) by about 2.8-fold in strain S2 with a
J23108 promoter upstream of vioD, the biosynthetic enzyme
that diverts the pathway flux toward violacein,6 whereas in strain
S3, where the vioD promoter remained unchanged, the
conversion to 3 increased by about two-fold compared with
that in the original strain S1 (Figure S3). This shows that it is
possible to fine-tune the proportion of chlorinated analogue by
changing the promoter strength of pathway enzymes, and the
optimization of the fermentation protocols such as the length of
incubation, temperature, and media conditions might further
increase both the proportion and the total amount of chlorinated
analogues.8
Further derivatization, through chemical cross-coupling, of
new-to-nature, halogenated natural product analogues gener-
ated by a synthetic biological strain, was first demonstrated with
pacidamycins.19 We applied a similar strategy by first feeding 5-
bromo-D,L-tryptophan to E. coli cells expressing VioABCDE to
generate 5′-bromo-violacein and 5′-bromo-deoxyviolacein,
which were detected by LC-HRMS/MS (Table S3). We could
not find the mass corresponding to dibromo-deoxyviolacein
(C20H11N3O2Br2, calc. [M + H]
+ m/z = 483.9291), 5-bromo
isomers of deoxyviolacein (C20H12N3O2Br, calc. [M + H]
+ m/z
= 406.0186), or prodeoxyviolacein (C20H12N3OBr, calc. [M +
H]+ m/z = 390.0237). We hypothesize that this is due to the
preference of VioE in catalyzing the formation of 5′-Br-
prodeoxyviolacein, in accordance with the isomer preference
previously observed with various other violacein and deoxy-
violacein analogues.24 We then proceeded to screen a series of
conditions that might facilitate Suzuki−Miyaura cross-coupling;
however, because of low titers of 5′-bromo-violacein and 5′-
bromo-deoxyviolacein available in the crude extract and
challenges relating to the separation of these compounds that
showed a propensity for pi-stacking, the isolation of products for
further characterization and bioassays of the cross-coupling
product proved difficult. We thus focused on systemically
identifying conditions that would allow direct cross-coupling in
crude extracts, which identified the optimal conditions for
derivatization. The corresponding cross-coupling products 5′-
(p-tolyl)-violacein (7) and 5′-(p-tolyl)-deoxyviolacein (8) were
detected in the cross-coupling mixture by LC-HRMS/MS
(Figure 4a, Table S3). Having identified the optimized
conditions for cross-coupling at low concentrations, we
performed the cross-coupling reaction with a selection of 15
aryl boronic acids chosen to sample a wide range of steric and
electronic variations, which gave a total of 20 new cross-coupled
analogues of violacein and deoxyviolacein (Table S4). We
observed that whereas boronic acids with electron-donating
groups (e.g., p-methoxyphenylboronic acid) gave better yields
and MS/MS data were obtained, for those with electron-
withdrawing groups (e.g., p-formylphenylboronic acid), onlyMS
data were obtained due to the lower conversion and the more
Figure 4. Further derivatization of violacein and deoxyviolacein analogues via Suzuki−Miyaura cross-coupling reactions directly in crude extracts. (a)
Optimized conditions for the cross-coupling reaction directly in crude extracts. The coupling partner indicated is p-tolyl-boronic acid. (b) Starting
from indole, 5′-bromo-deoxyviolacein (6) was synthesized in two steps and used for preparative scale cross-coupling to afford the product (17), which
was isolated and characterized by 1H NMR analysis.
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difficult electrospray ionization of the corresponding violacein
analogues (Table S3). Pleasingly, even boronic acid pinacol
esters were successfully converted into the corresponding
violacein product (e.g., p-cyanophenylboronic acid pinacol
ester). In summary, the optimized conditions showed that a
variety of cross-coupling analogues could be synthesized without
the need for purification prior to cross-coupling, allowing for
rapid access to potential cross-coupling products.
The attempts to isolate brominated violaceins from the cell
culture extracts proved challenging due to low titers of the
desired compounds and coelution as mixtures during chromato-
graphic purifications. Hence we decided to synthesize 5′-bromo-
deoxyviolacein (6), which will be useful as a synthetic standard
and for the preparative scale cross-coupling reaction. To this
end, we adapted a two-step protocol reported for the synthesis of
violacein analogues.23 The condensation of the 3-acylated
intermediate (characterized with 1H and 13CNMR in Figure S4)
with 5-bromo-isatin proved challenging due to the formation of
a mixture of products. However, the desired product 6
(characterized with 1H NMR in Figure S5) was obtained in
15% yield after two difficult chromatographic purification steps,
further highlighting the benefits of the engineered biosynthesis.
The LC retention time and LC-HRMS/MS analysis of the
synthetic product matched with biosynthetic 6 and confirmed
the identity, as depicted (Figure S6). Furthermore, the cross-
coupling of synthetic 6 with p-carboxyphenylboronic acid
proceeded with a >70% yield based on the LC-HRMS analysis;
the product 17 was isolated (41% yield) from the crude reaction
by an extractive workup (Figure 4b). The cross-coupling
partner, p-carboxyphenylboronic acid, was selected for this
reaction based on its polarity to improve the purification of the
target compound generated. In the case of the tolyl derivative,
product 8 had a markedly different retention time from starting
material 6, eluting later, whereas product 17 eluted earlier than
the startingmaterial on our purification system. The product was
characterized by LC-HRMS/MS (Figure S7) and 1H and COSY
NMR (Figure S8) analyses. These cross-coupling conditions
provide a route to generate a diverse library of violacein
analogues.
Combining the strengths of biosynthesis and organic
synthesis, our GenoChemetic approach in generating diverse
compounds has proven to be fruitful in exploring the chemical
space of natural products and their derivatives. In this study,
inspection of the biosynthetic assembly of violacein and crystal
structure analyses of the first enzyme L-tryptophan oxidase VioA
suggested that various tryptophan substrate analogues could be
enzymatically processed. We utilized this finding and designed
experiments combining biosynthesis and chemical synthesis to
enable rapid access to six new halogenated violacein and
deoxyviolacein analogues. Furthermore, we have expanded this
collection of compounds further via Suzuki−Miyaura cross-
coupling reactions exploiting a brominated analogue of
violacein, accessing an additional series of 20 violacein or
deoxyviolacein coupling products. However, the ability to carry
out these synthetic diversifications selectively on the halome-
tabolites as components of a crude cell extract is limited by the
poor titers of the desired halogenated compounds and complex
mixtures that render isolation more difficult than traditional
synthetic routes. Therefore, further optimization of the
biosynthesis of halometabolites to increase the purity or yield
of the desired compounds or fine-tuning of cross-coupling
conditions should pave the way toward an improved
derivatization efficiency via cross-coupling in crude extracts.
Nonetheless, the combination of synthetic chemistry with
synthetic biology provides a more sustainable approach with the
potential for applications toward generating analogues of natural
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